Advances of Targeted Therapy in Cervical Cancer

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gynecologic Oncology".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 321

Special Issue Editors


E-Mail Website
Guest Editor
Dipartimento interdisciplinare di Medicina (DIM), Università degli studi di Bari Aldo Moro, 70121 Bari, Italy
Interests: cervical cancer; ovarian cancer; endometrial cancer

E-Mail Website
Guest Editor
2nd Unit of Obstetrics and Gynecology, Department of Biomedical and Human Oncological Science (DIMO), University of Bari, 70124 Bari, Italy
Interests: cervical cancer; ovarian cancer; endometrial cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Oncology Unit, IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy
Interests: gynecological tumors; genito-urinary tumors; immunotherapy; PARPis; meta-analysis; biomarkers

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue focused on the advances of targeted therapy in cervical cancer (CC). CC still represents the fourth most common cancer among the female population, and the fourth cause of cancer-related deaths worldwide. It is typically present among younger patients, with a median age of 49 years at diagnosis. In the metastatic stage, the 5-year survival rate is only 17.6%. Platinum-based chemotherapy represents a milestone for the treatment of CC; however, therapeutic options after progression and survival are limited. Therefore, the search for new therapeutic approaches is still an unmet need for CC.

The Cancer Genome Atlas (TCGA) project focused on identifying altered pathways that may lead to tumorigenesis, as well as be used as prognostic or therapeutic markers. TCGA work led to the identification of genetic aberrations and pathways that can be exploited therapeutically as new potential targeted therapy markers. This Special Issue aims to collect papers of targeted therapies in CC. Though all studies regarding targeted therapy for CC will be considered for publishing, priority will be given to original research regarding advances and innovations of targeted therapies for CC, giving future perspectives and outlining how these advances will reshape the future CC therapeutic scenario. Areas of special interests could be, but are not limited to, the newest targeted therapy pathways, such as VEGF/VEGFR and CD274 (PD-L1), and more generally the use of ICIs, EGFR, mTOR, PARP and the role of PARPis, vaccines and antibody–drug conjugates.

We look forward to receiving your contributions.

Dr. Vera Loizzi
Dr. Gennaro Cormio
Dr. Brigida Anna Maiorano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cervical cancer
  • targeted therapy
  • HPV
  • ICI
  • immunotherapy
  • VEGF
  • vaccine
  • PARP

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop